Emicizumab as prophylaxis in people with severe congenital haemophilia A without factor VIII inhibitors (all ages)

Document first published:: 21 August 2019
Page updated:: 21 August 2019
Topic:: Specialised commissioning
Publication type:: Policy or strategy, Report

NHS England will commission emicizumab as prophylaxis in people with severe congenital haemophilia A without factor VIII inhibitors in accordance with the criteria outlined in this policy.

Document

Emicizumab as prophylaxis in people with severe congenital haemophilia A without factor VIII inhibitors (all ages)

Emicizumab as prophylaxis in people with severe congenital haemophilia A without factor VIII inhibitors (all ages)

PDF
308 KB
22 pages

Document

Evidence Review

Evidence Review

PDF
446 KB
35 pages

Document

Consultation Report

Consultation Report

PDF
103 KB
4 pages

Document

CPAG Summary Report

CPAG Summary Report

PDF
103 KB
5 pages

Document

Clinical Panel Report

Clinical Panel Report

PDF
129 KB
2 pages